Shanghai, April 18, 2023, IMPACT Therapeutics today presents the discovery and early development of WEE1 inhibitor IMP7068 at the 2023 American Association for Cancer Research (AACR) Annual Meeting in Orlando on April 14-19, 2023.

Poster Presentations:

Title: Discovery and Development of a Potent and Highly Selective WEE1 Inhibitor IMP7068

Date&Time: Monday, April 17, 2023, 1:30 PM – 5:00 PM

Location: Section 31, PO.CH01.04

Poster ID: 3091

Summary of Results

IMPACT Therapeutics has identified a novel, potent, and selective WEE1 inhibitor IMP7068. IMP7068 exhibits superior WEE1/PLK1 selectivity (>435 fold) compared to AZD1775. IMP7068 also shows potent cytotoxicity against a wide range of cancer cell lines. In addition, IMP7068 has desirable PK profiles with long half-life and high exposure in preclinical species. Anti-tumor efficacy of IMP7068 has been demonstrated in mice CDX models of colorectal cancer LoVo, non-small cell lung cancer NCI-H1299 and a PDX model of uterine cancer UT5318 with good dose-response tumor inhibition and tolerability. IMP7068 is currently in a phase I study to evaluate its safety, tolerability, pharmacokinetics, and anti-tumor activity in patients with advanced solid tumors (ClinicalTrials.gov Identifier: NCT04768868).  

About IMPACT Therapeutics

IMPACT Therapeutics is a biopharmaceutical company dedicated to the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality. IMPACT Therapeutics has assembled one of the most comprehensive DNA damage responses (DDR) global pipeline of novel drug candidates generated by in-house discovery efforts and is expanding to other novel synthetic lethality targets to broaden its pipeline. IMPACT pipeline products include PARP inhibitor (Senaparib/ IMP4297), WEE1 inhibitor (IMP7068), ATR inhibitor (IMP9064) and other novel DDR pathway inhibitors. The lead clinical program, PARP inhibitor Senaparib (IMP4297), is in Phase II/III studies for ovarian cancer, small cell lung cancer and other indications worldwide, including China. Senaparib’s preliminary clinical data demonstrated superior tolerability and wider therapeutic window compared with other PARPi. The phase III clinical study of Senaparib for advanced ovarian cancer maintenance treatment following first-line therapy has met primary endpoint. Phase I study of Wee1 inhibitor IMP7068 is conducted globally, including the United States and China. In addition, ATR inhibitor IMP9064 has also been undergoing phase I clinical studies in multiple countries and regions such as the United States and China. Hedgehog pathway inhibitor IMP5471 has received IND approval from NMPA to initiate clinical studies in China.

For more information, please contact:

http://www.impacttherapeutics.com

Email: info@impacttherapeutics.com